HER 2/neu protein expression in colorectal cancer

B Schuell, T Gruenberger, W Scheithauer, Ch Zielinski, F Wrba, B Schuell, T Gruenberger, W Scheithauer, Ch Zielinski, F Wrba

Abstract

Background: Conflicting data exist about the prevalence of HER-2/neu overexpression in colorectal cancer ranging from 0 to 83 %. In our study we tried to clarify the extent of expression and its relationship to clinicopathological parameters.

Methods: This study involved 77 specimens of malignant colorectal cancer lesions of surgically resected patients. HER-2/neu immunohistochemistry was performed using the Hercep-Test Kit.

Results: Out of 77 specimens, 56 were Her-2/neu negative (70%), 20 (26%) showed a barely immunostaining (1+), only 1 (1%) was moderately (2+) and 2 (3%) were strongly positive (3+). Her-2/neu staining (moderately and strongly positive) was only detected in primary tumours of patients with confirmed metastases. No relationship was found between membranous HER-2 expression and patients' gender or differentiation. The median survival time of patients with positive HER-2/neu immunostaining was 21 versus 39 months in patients without HER-2/neu expression (p = 0.088).

Conclusion: The c-erbB protein expression was observed in colorectal cancer but rarely in the therapeutic range (2+ and 3+). There was no significant association with tumour grade, gender, localization of the primary tumour or survival. These data indicate that c-erbB-2 is unlikely to play a major role in the therapeutic management of colorectal cancer.

Figures

Figure 1
Figure 1
Survival according to Her-2/neu status. ---- HER-2/Neu neg. HER-2/Neu pos.

References

    1. Landis SH, Murray T, Bolden S, Wings PA. Cancer statistics. CA Cancer J Clin. 1999;49:8–13.
    1. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II Trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208. doi: 10.1200/JCO.2004.10.182.
    1. Schlessinger J. Cell signaling by receptor tyrosine kinase. Cell. 2000;103:211–25. doi: 10.1016/S0092-8674(00)00114-8.
    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogenes. Science. 1987;234:177–182.
    1. Saranath D, Panchal RG, Nair R, Metha AR, Sanghavi VD, Deo MG. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer. 1992;28B:139–143.
    1. Rusch V, Baselga J, Cordon-Carlo , Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligand in primary non-small cell lung cancers and adjusent benign lung. Cancer Res. 1993;53:2379–2385.
    1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SA, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712.
    1. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Realmond C, Schlessinger J, Lippman ME, King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein in primary breast cancer. J Clin Oncol. 1990;8:103–112.
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001;344:783–92. doi: 10.1056/NEJM200103153441101.
    1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Salamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ et, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2000;20:719–26. doi: 10.1200/JCO.20.3.719.
    1. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 2001;120:1713–9. doi: 10.1053/gast.2001.24844.
    1. Ross JS, McKenna BJ. The Her-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19:554–68. doi: 10.1081/CNV-100103852.
    1. Caruso ML, Valentini AM. Immunhistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer. Anticancer Res. 1996;16:3813–8.
    1. Osako T, Miyahara M, Uchino , Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patients survival. Oncology. 1998;55:548–55. doi: 10.1159/000011911.
    1. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Primorac D, Sonicki Z, Spaventi S, Pavelic K, Spaventi R. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112:1103–13. doi: 10.1016/S0016-5085(97)70120-3.
    1. McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, McLeod HL. C-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002;86:568–573. doi: 10.1038/sj.bjc.6600127.
    1. Beahrs OH. Staging of cancer of the colon and rectum. Cancer. 1992;70:1393–6.
    1. Hermanek P, Altendorf A. Pathol Res Pract. 1981;173:1–11.
    1. Kirschbaum MH, Yarden Y. The ErbB/Her family of receptor tyrosine kinase a potential target for chemoprevention of epithelial neoplasm. J Cell Biochem Suppl. 2000;34:52–60. doi: 10.1002/(SICI)1097-4644(2000)77:34+<52::AID-JCB10>;2-X.
    1. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994;29:127–138. doi: 10.1007/BF00666188.
    1. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 1994;64:127–54. doi: 10.1016/0163-7258(94)90036-1.
    1. Nathason DR, Culliford AT, Shia J, Chen B, D'Alessio MD, Zeng Z, Nash G, Gerald W, Barany F, Paty P. HER-2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003;105:796–802. doi: 10.1002/ijc.11137.
    1. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004;108:540–548. doi: 10.1002/ijc.11599.
    1. Lazaris AC, Theodoroporlos GE, Anastassopulos , Nakopoulou L, Panoussopoulus D, Papadimitriou K. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol. 1995;10:661–8.
    1. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S, Tahara E. Association of epidermal growth factor-related peptides and type I receptor tyrosine receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol. 1995;25:240–9.
    1. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Ealko C, Day R, Chen HX, Finkelstein S. Low expression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trail. Cancer Invest. 2004;22:858–65. doi: 10.1081/CNV-200039645.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel